Project description
Faster diagnosis of antimicrobial resistance
The injudicious use of antibiotics has led to the emergence of antimicrobial resistance (AMR) caused by bacteria which cannot be killed by existing drugs. AMR threatens routine hospital-based procedures and leads to a significant number of deaths every year. The aim of the EU-funded Nanosynex project is to put forward a disruptive microfluidic-based technology that significantly cuts down on sample processing time and delivers faster diagnosis of AMR. Introduction of the device into routine diagnostic practice will help clinicians make more informed and accurate decisions on antibiotic therapies to treat their patients.
Objective
Antimicrobial Resistance (AMR) has been declared as one of today’s biggest global threats as 700,000 people die due AMR.
Inappropriate antibiotic use is widespread. In the general practice, physicians commonly use empirical antibiotic therapy (highly inaccurate), since AST results take too long. Nanosynex product provides a revolutionary ultra-fast AST technology that will disrupt the market by cutting time to results in more than half (from 9 – the fastest - to 4 hours). This will allow physicians to get same-day results (i.e. in less than 5 hours) for AST, a unique feature that will save at least one day of hospitalization per patient and help reducing the spread of resistant bacteria. A successful validation through this Phase-1 of the technology and our revenue models will be fundamental to demonstrate evidence of user satisfaction A successful validation through this Phase-1 of the technology and our revenue models will be fundamental to demonstrate evidence of user satisfaction. Nanosynex Ltd is an Israeli start-up providing health-care systems with a rapid microfluidic diagnostic solution for faster and personalised antibiotic treatment. The company intends to scale up in the European market first, thanks to its strategic partnership with Biosynex, a leading French rapid diagnostic test (RDT) company that has an established distribution network in Europe, Middle East and Africa (60+ countries). Afterwards, Nanosynex will expand internationally. Nanosynex forecast to generates 14.7M€ , and and at EBITDA of 3.4M€ by 2024
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- natural sciences biological sciences microbiology bacteriology
- social sciences economics and business business and management business models
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs antibiotics
- engineering and technology medical engineering medical laboratory technology diagnostic technologies
- medical and health sciences basic medicine pharmacology and pharmacy drug resistance antibiotic resistance
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.3. - PRIORITY 'Societal challenges
See all projects funded under this programme -
H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-1 - SME instrument phase 1
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-EIC-SMEInst-2018-2020
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
5126112 Bnei Brak
Israel
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.